The Trump administration raises tariffs on South Korean goods to 25%, citing Seoul's 'disproportionate' regulatory campaign against U.S. e-commerce leader Coupang. The move threatens to strain a key Asian alliance built on decades of security and economic cooperation.
The explosive demand for AI is triggering a seismic shift in commercial real estate, as investors pour capital into specialized data centers designed to handle the immense power and cooling needs of next-generation computing.
India's Supreme Court has issued a stern warning to Meta's WhatsApp, questioning its data monetization and user consent model in a market where the app holds a dominant position. The court has temporarily barred data sharing pending a detailed examination.
As the TSX rides a wave of robust Q4 earnings, savvy investors are looking past the blue chips. We delve into three lesser-known Canadian companies—spanning energy, aerospace, and energy services—that combine solid fundamentals with strategic moves to capitalize on current economic tailwinds.
Aerospace and defense supplier TransDigm Group Inc. (NYSE:TDG) reported robust fourth-quarter results, with revenue climbing 13.9% year-over-year to $2.29 billion, surpassing analyst expectations. The company's strong performance and optimistic full-year outlook underscore its entrenched position in a recovering commercial and resilient defense aviation market.
Pharmaceutical giant Merck & Co. reported fourth-quarter revenue that surpassed Wall Street forecasts, driven by robust demand for its key products. However, a more conservative full-year sales projection and a sharp expected decline in earnings for the coming year tempered the positive results, sending shares lower in after-hours trading.
Packaging giant Ball Corporation (NYSE: BALL) delivered a robust fourth-quarter performance for 2025, surpassing revenue and profit expectations. The company's focus on operational discipline and shareholder returns, including $1.54 billion in buybacks and dividends, capped a record year.
Major German business associations are urging parliament and the government to suspend the national Supply Chain Due Diligence Act, arguing recent amendments fail to provide real relief and threaten competitiveness ahead of stricter EU rules.
GE HealthCare secures dual US and European regulatory approvals for its new Allia Moveo imaging system, designed to enhance patient comfort and streamline clinical workflows in minimally invasive procedures.
Amazon Web Services warns that multi-year delays in securing power grid connections are jeopardizing its data center investments across Europe, highlighting a critical infrastructure bottleneck for the continent's digital and industrial ambitions.
CNBC's Jim Cramer pushes back against recent skepticism surrounding Amazon, arguing the market is overlooking the tech giant's fundamental resilience and diversified growth engines.
Institutional ownership reaches 39% at European copper producer Aurubis AG, granting major influence and exposure to the firm's performance as shares surge over 120% in a year.
Aquestive Therapeutics faces a regulatory delay for its sublingual epinephrine film, Anaphylm, after the FDA raised concerns primarily about its packaging and labeling. The company views the issues as solvable and is moving forward with redesigns and new studies, aiming for a 2026 resubmission while advancing parallel filings abroad.
Biosimilars developer Alvotech (NASDAQ: ALVO) presents a complex picture for investors, with recent short-term share price gains starkly contrasted by a punishing 57% decline over the past year. As the stock trades at a significant discount to some analyst targets, the market debates whether this signals a prime opportunity or reflects deeper, unresolved challenges.
CNBC's Jim Cramer suggests that upcoming clinical trial updates for Eli Lilly's GLP-1 drugs, rather than quarterly earnings, are the primary catalyst investors should watch for potential stock movement.
CNBC's Jim Cramer includes Pfizer in his weekly game plan but voices unease over the pharmaceutical giant's pipeline, questioning where its next blockbuster drug will come from despite an attractive dividend yield.
CNBC's Jim Cramer has placed PepsiCo on his radar, expressing specific concerns that the consumer giant's Frito-Lay snack division faces headwinds from the rising popularity of GLP-1 weight-loss drugs, even as the stock shows recent strength.
As The Walt Disney Company prepares to report earnings, CNBC's Jim Cramer places the media giant under scrutiny, highlighting persistent challenges in its streaming business and theme park operations that investors will be watching closely.
As the artificial intelligence boom enters a new phase of enterprise deployment, investors are looking beyond pure software to the foundational hardware layer. We analyze three key companies powering the AI revolution and why their roles may offer a compelling, lower-risk investment thesis this February.
U.S. stock futures ticked up Tuesday as investors braced for a heavy slate of corporate results, while a partial government shutdown forced a delay of January's crucial employment report, adding uncertainty to the economic outlook.
